Device and method for testing in-vivo ferrofluid drug transport performance
By controlling the magnetic field strength and position of the magnetic block and the ferrofluid droplet, combined with fluorescent particle labeling, the Rosensweig instability and leakage problems of ferrofluid in vivo drug delivery were solved, achieving reliable detection and quantification.
Patent Information
- Application Number
- CN202510923912.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-04
- Publication Date
- 2025-11-18
AI Technical Summary
In existing technologies, ferrofluids in in vivo targeted drug delivery suffer from Rosensweig instability and lack of in-situ detection of drug leakage. Traditional in vitro release experiments cannot simulate the in vivo environment, leading to inaccurate detection.
An in vivo ferrofluid drug transport performance testing device was designed. By controlling the magnetic field strength and position between the magnetic block and the ferrofluid droplet, combined with fluorescent particle labeling, the device can achieve quantitative determination of Rosensweig instability and precise quantification of drug leakage rate.
The quantitative determination of the critical magnetic field of Rosensweig instability was achieved, the magnetic field parameters were optimized, a reliable basis for drug delivery was provided, and the leakage rate was accurately quantified, improving the repeatability and reliability of the detection.
Smart Images
Figure CN120971384A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of biotechnology, and particularly relates to an in-vivo ferrofluid drug transportation performance testing device and a testing method. BACKGROUND
[0002] At present, the application of ferrofluids in targeted drug delivery faces two key problems: one is the lack of detection means for in-vivo steady-state distribution, and the surface of the ferrofluids is prone to produce Rosensweig instability phenomenon under high magnetic field conditions, which seriously affects the effect of the ferrofluids on drug transportation; the other is the lack of in-situ detection method for drug leakage, and the traditional in-vitro release experiment (such as dialysis method) cannot simulate the in-vivo environment such as blood vessel shear force and dynamic change of magnetic field, resulting in inaccurate leakage risk assessment. SUMMARY
[0003] The present application aims to provide an in-vivo ferrofluid drug transportation performance testing device to solve one or more technical problems in the prior art, and at least provide a beneficial choice or create conditions.
[0004] The in-vivo ferrofluid drug transportation performance testing device according to the first aspect of the present application comprises:
[0005] a mounting table;
[0006] a testing table installed on the mounting table, wherein the testing table is provided with a testing substrate for placing a ferrofluid droplet, and the ferrofluid droplet is wrapped with fluorescent particles;
[0007] a moving module installed on the mounting table, wherein the moving module is provided with a movable support that can move forward and backward, the movable support is provided with a movable table that can move up and down, the movable table is provided with a magnetic block, the magnetic block is located below the testing table, the magnetic field strength acting on the ferrofluid droplet is related to the up-down height of the magnetic block, and the magnetic block can be used to drive the ferrofluid droplet to move in the same direction on the testing substrate when the magnetic block moves forward and backward;
[0008] a camera, wherein the shooting area of the camera faces the testing substrate;
[0009] an excitation light source, wherein the light-emitting area of the excitation light source faces the testing substrate.
[0010] The in-vivo ferromagnetic fluid drug transportation performance testing device according to the embodiment of the present application has at least the following beneficial effects: since the moving module has the freedom of moving up and down and moving forward and backward, the magnetic field strength received by the ferromagnetic fluid droplet can be changed by controlling the up-down distance between the magnetic block and the ferromagnetic fluid droplet, so as to detect the magnetic field strength received by the ferromagnetic fluid droplet when it is in the Rosensweig instability state, thereby establishing the magnetic field strength interval threshold at which the ferromagnetic fluid droplet maintains the stable state, so as to avoid the failure of the experiment due to the Rosensweig instability state of the ferromagnetic fluid droplet in the subsequent experiment; on this basis, the ferromagnetic fluid droplet is driven to move in the same direction on the test substrate by controlling the forward-backward position of the magnetic block, since the ferromagnetic fluid droplet is wrapped with fluorescent particles, the fluorescent particles will be left on the moving path during the movement of the ferromagnetic fluid droplet, the left path of the fluorescent particles can be clearly photographed by the camera under the excitation of the excitation light source, and the leakage rate of the nano drug in the targeted transportation process is accurately quantified through image analysis; compared with the prior art, the present application realizes the quantitative determination of the Rosensweig instability critical magnetic field, provides a reliable basis for optimizing the magnetic field parameters, and accurately quantifies the leakage rate of the nano drug in the targeted transportation process by photographing and analyzing the left path of the fluorescent particles of the ferromagnetic fluid droplet during the targeted transportation, which has the advantages of high repeatability, reliable detection and the like.
[0011] According to some embodiments of the present application, the moving module comprises a forward-backward moving mechanism and an up-down moving mechanism, the forward-backward moving mechanism drives the support column to move in the forward-backward direction, and the up-down moving mechanism is arranged on the support column and drives the movable table to move in the up-down direction.
[0012] According to some embodiments of the present application, the moving speed of the forward-backward moving mechanism and the up-down moving mechanism is not higher than 0.05 mm / s.
[0013] According to some embodiments of the present application, the in-vivo ferromagnetic fluid drug transportation performance testing device further comprises a gauss meter, which is used to record the magnetic field strength of the ferromagnetic fluid droplet received by the magnetic block.
[0014] According to some embodiments of the present application, the test substrate is a polydimethylsiloxane substrate, and the ratio of polydimethylsiloxane to curing agent is 10:0.8 to 10:1.2.
[0015] According to some embodiments of the present application, the excitation light source is an ultraviolet light source.
[0016] According to some embodiments of the present application, the camera is an sCMOS camera.
[0017] According to some embodiments of the present application, the camera is configured with an emission filter of a specific wavelength.
[0018] According to some embodiments of the application, the mounting table is a shock-absorbing table.
[0019] According to the test method of the second aspect of the application, the in-vivo ferrofluid drug transportation performance test device is applied, and the method comprises the following steps:
[0020] When the magnetic block is directly below the ferrofluid droplet, the moving module drives the magnetic block to move upward to approach the ferrofluid droplet, so as to change the magnetic field intensity of the ferrofluid droplet, and the camera photographs the morphology of the ferrofluid droplet; when the morphology of the ferrofluid droplet changes from surface stability to Rosensweig instability state, the moving module stops the upward movement of the magnetic block, and records the magnetic field intensity of the ferrofluid droplet;
[0021] The moving module drives the magnetic block to move downward to move away from the ferrofluid droplet, so that the morphology of the ferrofluid droplet changes from Rosensweig instability state to surface stability;
[0022] The moving module drives the magnetic block to move along the front-back direction, and the ferrofluid droplet follows the magnetic block to move in the same direction on the test substrate under the magnetic field line distribution of the magnetic block; under the irradiation of the excitation light source, the camera photographs the fluorescence signal of the residual particles of the ferrofluid droplet in the moving process;
[0023] The image processing and fluorescence intensity distribution analysis are performed on the images photographed by the camera, the residual area of the fluorescence signal is calculated, and the effect of the ferrofluid on the transportation of drugs is obtained.
[0024] Additional aspects and advantages of the application will be described in part in the description that follows, and will become apparent from the description that follows, or will be learned by practice of the application. BRIEF DESCRIPTION OF DRAWINGS
[0025] The above and / or additional aspects and advantages of the application will become apparent and be readily understood from the description that follows, including the appended drawings, in which:
[0026] Figure 1 is a structural schematic diagram of the in-vivo ferrofluid drug transportation performance test device provided by the embodiments of the application before the test starts;
[0027] Figure 2 is a structural schematic diagram of the in-vivo ferrofluid drug transportation performance test device provided by the embodiments of the application when the ferrofluid droplet appears Rosensweig instability state;
[0028] Figure 3is a structural schematic view of a device for testing in-vivo ferrofluid drug transportation performance provided by an embodiment of the present application, which is used for testing a nano drug targeting transportation leakage rate;
[0029] Figure 4 is a schematic view of a state of Rosensweig instability of ferrofluid.
[0030] In the drawings: 100 - mounting table, 200 - test table, 300 - moving module, 400 - camera, 500 - gauss meter, 600 - excitation light source, 210 - gantry, 700 - test substrate, 710 - ferrofluid droplet, 310 - forward and backward moving mechanism, 320 - up and down moving mechanism, 321 - support column, 322 - movable table, 800 - magnetic block, 900 - fluorescent particles. DETAILED DESCRIPTION
[0031] Embodiments of the present application are described below in detail, examples of which are shown in the drawings, wherein the same or similar reference signs represent the same or similar elements or elements having the same or similar functions throughout. The embodiments described below by referring to the drawings are exemplary, only for explaining the present application, and cannot be understood as a limitation of the present application.
[0032] In the description of the present application, it is understood that the orientation description, such as the orientation or position relationship indicated by up, down, front, back, left, right, etc. is based on the orientation or position relationship shown in the drawings, only for the convenience of describing the present application and simplifying the description, and therefore cannot be understood as a limitation of the present application.
[0033] In the description of the present application, the meaning of several is one or more, and the meaning of multiple is more than two. Greater than, less than, more than, etc. are understood as not including the number, and above, below, etc. are understood as including the number. If it is described as first, second, only for the purpose of distinguishing technical features, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features or the sequence of indicated technical features.
[0034] In the description of the present application, unless otherwise explicitly limited, the words such as setting, mounting, connecting, etc. should be understood in a broad sense, and the person skilled in the art can reasonably determine the specific meaning of the above words in the present application according to the specific content of the technical solution.
[0035] As Figure 1As shown, the in-vivo ferrofluid drug transport performance testing device according to the first aspect of the embodiment of the application comprises a mounting table 100, a testing table 200, a moving module 300, a camera 400, a gauss meter 500 and an excitation light source 600, wherein the mounting table 100 is the mounting reference for all components, and the surface thereof is flat and has no obvious undulation. The testing table 200 and the moving module 300 are both fixedly connected to the mounting table 100 through a base, while the camera 400, the gauss meter 500 and the excitation light source 600 are fixedly connected to the mounting table 100 through a support rod, which is used to lift the height of the three, so that they can be set high. At this time, the shooting area of the camera 400 and the light-emitting area of the excitation light source 600 are both directed to the testing table 200. Since the testing of the ferrofluid droplet 710 requires high precision, any vibration generated on the mounting table 100 will have a great impact on the test results. In order to reduce the influence of the working environment on the ferrofluid droplet 710 during the test and improve the measurement accuracy, the mounting table 100 can be selected as a shock-absorbing table in this embodiment.
[0036] A shock-absorbing table is a kind of experimental equipment specially used for isolating or reducing external vibration interference, and is widely used in high-precision measurement and precise instrument operation. The shock-absorbing table effectively isolates ground vibration, equipment vibration and environmental noise through passive or active control technology, so as to ensure the stability and accuracy of experimental data. The shock-absorbing table is mainly divided into passive shock-absorbing and active shock-absorbing. The passive shock-absorbing utilizes elastic materials such as rubber pads, springs or negative stiffness structures to absorb vibration energy, and reduces the resonance frequency through damping effect; while the active shock-absorbing detects vibration in real time through a sensor, drives a piezoelectric element to generate a reverse force to offset interference, and is suitable for dynamic environment.
[0037] In addition, the testing table 200 is supported by a gantry 210, which is fixedly connected to the mounting table 100 through a base. The testing table 200 is provided with a test substrate 700 for placing droplets. In this experiment, since the experiment is to test the treatment scheme of drug in-vivo targeting transport, the test substrate 700 is selected as a polydimethylsiloxane substrate, and the droplet is selected as a ferrofluid droplet 710. In order to make the test substrate 700 more close to the softness of human skin, the ratio of polydimethylsiloxane to curing agent is 10:0.8 to 10:1.2, and preferably 10:1.
[0038] In addition, the moving module 300 comprises a front-back moving mechanism 310 and an up-down moving mechanism 320, both of which comprise but are not limited to a screw moving mechanism, a gear and rack moving mechanism, a cylinder moving mechanism or an oil cylinder moving mechanism. In the embodiment, the moving mechanism needs to be controlled with high precision, and therefore the screw moving mechanism is preferred. The screw moving mechanism mainly comprises a structure, a servo motor, a screw and a nut block. The structure of the front-back moving mechanism 310 is fixedly connected to the mounting table 100 through a base. The screw is arranged in the structure in the front-back direction. The spindle of the servo motor is rigidly connected to the screw. The nut block is threadedly connected to the screw, and the nut block has a freedom degree of movement with the structure, so that when the servo motor is started, the nut block can advance or retreat with the forward and reverse rotation of the servo motor under the driving of the screw.
[0039] The nut block is fixedly connected with a support column 321. The structure of the up-down moving mechanism 320 can refer to the structure of the front-back moving mechanism 310. The support column 321 of the up-down moving mechanism 320 is equivalent to the structure of the front-back moving mechanism 310. The nut block of the up-down moving mechanism 320 is transversely connected with a movable table 322. Since the moving module 300 has the freedom degrees in the front-back direction and the up-down direction, the position of the movable table 322 in the front-back direction and the up-down direction can be adjusted with high precision by the corresponding servo motor.
[0040] Regardless of the structure of the moving module 300, the movable table 322 is located below the test table 200. The movable table 322 is provided with a magnetic block 800 fixedly connected to the movable table 322. Since the movable table 322 is located below the test table 200, the magnetic block 800 is also located below the test table 200, and the magnetic induction line of the magnetic block 800 can pass through the test table 200, the test substrate 700 and affect the ferromagnetic fluid droplet 710.
[0041] In order to correctly locate the magnetic block 800 directly below the ferromagnetic fluid droplet 710, the moving module 300 has a moving origin. When the moving module 300 is at the moving origin, the position of the magnetic block 800 in the front-back direction and the position of the magnetic block 800 in the up-down direction are reset. At the same time, the test substrate 700 is provided with a dropping mark, and the position of the dropping mark is directly opposite to the front-back origin of the magnetic block 800. When the operator places the ferromagnetic fluid droplet 710 on the dropping mark, the ferromagnetic fluid droplet 710 is located directly above the magnetic block 800, so as to save the position adjustment operation of the two.
[0042] When the magnetic block 800 is located directly below the ferrofluid droplet 710, the magnetic field strength of the magnetic block 800 acting on the ferrofluid droplet 710 is related to the height of the magnetic block 800. When the magnetic block 800 is closer to the ferrofluid droplet 710, the ferrofluid droplet 710 receives a stronger magnetic field; when the magnetic block 800 is farther away from the ferrofluid droplet 710, the ferrofluid droplet 710 receives a weaker magnetic field.
[0043] When the magnetic block 800 moves forward and backward, the magnetic field lines acting on the ferrofluid droplet 710 change, so the ferrofluid droplet 710 moves in the same direction along the test substrate 700 under the action of the magnetic field lines. That is, when the magnetic block 800 moves in the forward direction, the ferrofluid droplet 710 moves horizontally in the forward direction on the test substrate 700; when the magnetic block 800 moves in the backward direction, the ferrofluid droplet 710 moves horizontally in the backward direction on the test substrate 700, to simulate the real situation of in-vitro magnetic field controlling in-vivo magnetic-controlled drugs.
[0044] As shown in Figure 4 The ferrofluid is prone to Rosensweig instability phenomenon on the surface under high magnetic field conditions. When the ferrofluid exhibits Rosensweig instability phenomenon, the interface between the ferrofluid and other immiscible fluids will fluctuate, protrude or form sharp peaks, etc. This instability of the interface will destroy the originally relatively stable structure of the ferrofluid, making it difficult to accurately control the delivery path and position of the drug when transporting the drug, so that the drug cannot accurately reach the target position. Moreover, Rosensweig instability will cause the motion of magnetic particles in the ferrofluid to become disordered. The ferrofluid relies on the ordered arrangement and motion of magnetic particles under the action of an external magnetic field to realize the transportation of drugs. After the motion of the particles is disturbed, the ability and directionality of the particles to carry drugs will be affected, thereby reducing the efficiency and accuracy of drug transportation. Finally, due to the instability of the interface and the disorder of the motion of the magnetic particles, the ability of the ferrofluid to encapsulate drugs may decrease, leading to premature release of the drugs or leakage during transportation, and the drugs cannot be accurately transported to the designated position.
[0045] Therefore, it is necessary to establish a magnetic field strength interval threshold for the ferrofluid droplet 710 to maintain a steady state through testing, so as to avoid experimental failure due to the occurrence of Rosensweig instability state of the ferrofluid droplet 710 in subsequent experiments. As shown in Figure 2As shown, the test process is as follows: When the magnetic block 800 is directly below the ferrofluid droplet 710, the up-and-down moving mechanism 320 moves the magnetic block 800 upwards towards the ferrofluid droplet 710 to change the magnetic field strength experienced by the ferrofluid droplet 710. The camera 400 captures the shape of the ferrofluid droplet 710. When the shape of the ferrofluid droplet 710 changes from a surface stable state to a Rosensweig instability state, the up-and-down moving mechanism 320 stops the upward movement of the magnetic block 800, and the magnetic field strength experienced by the ferrofluid droplet 710 is recorded by the gaussmeter 500. At this time, the Hall chip end of the gaussmeter 500 is placed at the center of the test substrate 700. The initial data is converted into a time-magnetic field strength curve, and the data is analyzed to confirm the magnetic field strength range suitable for the horizontal movement of the ferrofluid droplet 710 without the occurrence of Rosensweig instability.
[0046] like Figure 3 As shown, to quantify the leakage rate of nanomedicines during targeted delivery, the operator labels the nanoparticles with fluorescent material before placing the ferrofluid droplet 710 onto the test substrate 700. In this embodiment, the fluorescently labeled nanoparticles are defined as fluorescent particles 900. The operator places the fluorescent particles 900 within the ferrofluid droplet 710 to simulate the nanomedicine. After establishing the threshold range of magnetic field strength for maintaining a steady state of the ferrofluid droplet 710, the magnetic block 800 is kept at a reasonable height, and the magnetic block 800 is moved along a predetermined direction by the forward and backward movement mechanism 310. The purpose is to control the distribution of magnetic field lines of the magnetic block 800 to drive the ferrofluid droplet 710 to move along the predetermined direction. After the ferrofluid droplet 710 moves outside the viewfinder of the camera 400, the forward and backward movement mechanism 310 stops the movement of the magnetic block 800.
[0047] As the magnetofluid droplet encapsulating fluorescent particles 900 moves on the test substrate 700, a small amount of fluorescent particles 900 may remain along its path. By photographing and analyzing the residual fluorescent particles 900, the leakage rate of the nanomedicine during targeted delivery can be obtained. Before the camera 400 captures the fluorescence path, a dark field is used to reduce interference from other light sources, and the excitation light source 600 is turned on to excite the fluorescent particles 900. By constructing an equipment platform with an sCMOS camera and a specific wavelength emission filter, the fluorescence signal of the residual particles of the magnetofluid droplet 710 during transportation is captured.
[0048] In order to enable the camera 400 to capture the fluorescent signal, it is necessary to use the excitation light source 600 to excite the fluorescent substance. In this embodiment, the excitation light source 600 can be selected as an ultraviolet light source, but in other embodiments, the excitation light source 600 can also be a blue light source or a green light source. Many common fluorescent substances have specific electronic transition structures, and their absorption spectra are usually in the ultraviolet or near-ultraviolet region. When they are irradiated with ultraviolet light, the electrons of these fluorescent substances will transition from the ground state to the excited state, and then the electrons will return from the excited state to the ground state and emit fluorescent light with a longer wavelength than the excitation light.
[0049] The sCMOS camera is a high-sensitivity camera with high resolution, high sensitivity, low noise, high frame rate, wide dynamic range, and other advantages, and is very suitable for experimental shooting. The image after shooting can be analyzed and processed through specific software.
[0050] The fluorescent substance emits fluorescent light after being irradiated by the excitation light. Different fluorescent substances emit fluorescent light with a specific wavelength range. In this embodiment, a fluorescent substance with a fluorescent wavelength range near 525 nm can be selected. Correspondingly, a 525 nm emission filter is configured on the camera 400 side. The main function of the 525 nm emission filter is to allow the fluorescent light emitted by the fluorescent substance on the ferrofluid droplet 710 to pass through, and to block other wavelengths of light, thereby laying the foundation for subsequent imaging.
[0051] The image captured by the sCMOS camera is saved and image processing is performed. The Imagej software is used to analyze the fluorescence intensity distribution of the image, and the residual area of the fluorescent signal is calculated to accurately quantify the leakage rate of the nanodrug during targeted transportation, thereby obtaining the effect of the ferrofluid transporting the drug.
[0052] The ferrofluid is formed by suspending nanoscale magnetic particles in a carrier liquid, and its viscosity is affected by the volume fraction of the particles and the surfactant. Experiments have shown that for every 1% increase in the volume fraction of solid particles, the viscosity of the ferrofluid will increase significantly. In the body, high viscosity can greatly increase the resistance of fluid movement. The movement of the ferrofluid depends on the magnetic force generated by the external magnetic field gradient. In addition to overcoming the viscous resistance of the fluid, in in vivo applications, in order to avoid tissue damage, the magnetic field gradient is usually set to be weak, resulting in limited net driving force for the ferrofluid. Superimposed on the above factors, in the in vitro magnetic field implementation of the drug targeted transportation treatment scheme in the body, the ferrofluid as a transportation carrier has a slow moving speed, generally not higher than 0.05 m / s, and generally 0.01 m / s. As a test, in this embodiment, the moving platform 322 moves at a speed of 0.01 mm / s, simulating the actual situation.
[0053] The test method according to the second aspect of the present application uses the in-vivo ferrofluid drug transportation performance test device according to the first aspect of the present application, and comprises the following steps:
[0054] S100. The nanoparticles are fluorescently labeled, and then the ferrofluid droplet 710 is used to wrap the fluorescently labeled nanoparticles. The moving module 300 resets the initial position of the magnetic block 800, and the operator places the ferrofluid droplet 710 wrapped with the fluorescent particles 900 on the drop mark of the test substrate 700. At this time, the ferrofluid droplet 710 is directly above the magnetic block 800.
[0055] S200. The up-and-down moving mechanism 320 drives the magnetic block 800 to move upwards to approach the ferrofluid droplet 710, so as to change the magnetic field intensity to which the ferrofluid droplet 710 is subjected. The camera 400 photographs the morphology of the ferrofluid droplet 710. When the morphology of the ferrofluid droplet 710 changes from the surface stability to the Rayleigh instability state, the up-and-down moving mechanism 320 stops the upward movement of the magnetic block 800. The magnetic field intensity to which the ferrofluid droplet 710 is subjected is recorded by the Gauss meter 500. The initial data is converted into a time-magnetic field intensity curve, and the data is analyzed to confirm the magnetic field intensity interval suitable for the horizontal movement of the ferrofluid droplet 710 without Rayleigh instability.
[0056] S300. The up-and-down moving mechanism 320 drives the magnetic block 800 to move downwards to move away from the ferrofluid droplet 710, so that the morphology of the ferrofluid droplet 710 changes from the Rayleigh instability state to the surface stability. At this time, the magnetic block 800 is at a reasonable height of the magnetic field intensity interval threshold. At this height, the magnetic block 800 will not cause the ferrofluid droplet 710 to produce Rayleigh instability due to being too close to the ferrofluid droplet 710, and can drive the ferrofluid droplet 710 to move in the same direction on the test substrate 700 through horizontal movement.
[0057] S400. The front-and-back moving mechanism 310 drives the magnetic block 800 to move in a predetermined direction. The ferrofluid droplet 710 follows the magnetic block 800 to move in the same direction on the test substrate 700 under the magnetic field line distribution of the magnetic block 800. Under the irradiation of the excitation light source 600, the camera 400 photographs the fluorescent signal of the residual particles of the ferrofluid droplet 710 in the moving process. After the ferrofluid droplet 710 moves out of the viewfinder frame of the camera 400, the front-and-back moving mechanism 310 stops the movement of the magnetic block 800.
[0058] S500. The image photographed by the camera 400 is saved and image processing is performed. The image is analyzed for fluorescent intensity distribution by Imagej software, and the residual area of the fluorescent signal is calculated to accurately quantify the leakage rate of the nanodrug in the targeted transportation process, so as to obtain the effect of the ferrofluid drug transportation.
[0059] Compared with the prior art, the present technology realizes the quantitative determination of the critical magnetic field of Rosenstweig instability, provides a reliable basis for optimizing the magnetic field parameters, and through shooting and analyzing the residual path of the fluorescent particles 900 when the ferrofluid droplets 710 are transported to the target, the leakage rate of the nanodrug in the targeted transport process is accurately quantified, which has the advantages of high repeatability, reliable detection and the like.
[0060] Since the test method adopts all the technical solutions of all the above embodiments, it at least has all the beneficial effects brought by the technical solutions of the above embodiments, which will not be repeated here.
[0061] The embodiments of the present application are described in detail above in combination with the drawings, but the present application is not limited to the above embodiments, and various changes can be made within the knowledge range possessed by those skilled in the art in the technical field without departing from the purpose of the present application.
Claims
1. An in vivo ferrofluid drug transport performance testing device, characterized in that, The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device.
2. The in-vivo ferrofluid drug transport performance testing device according to claim 1, characterized in that: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
3. The in-vivo ferrofluid drug transport performance testing device according to claim 2, characterized in that: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
4. The in-vivo ferrofluid drug transport performance testing device of claim 1, wherein: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
5. The in-vivo ferrofluid drug delivery performance testing device of claim 1, wherein: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
6. The in-vivo ferrofluid drug transport performance testing device of claim 1, wherein: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
7. The in-vivo ferrofluid drug transport performance testing device according to claim 6, characterized in that: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
8. The in-vivo ferrofluid drug transport performance testing device according to claim 7, characterized in that: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
9. The in-vivo ferrofluid drug transport performance testing device of claim 1, wherein: The application relates to an in-vivo ferrofluid drug transportation performance testing device.
10. Test method, characterized in that, The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo ferrofluid drug transportation performance testing device. The application relates to an in-vivo The moving module (300) drives the magnetic block (800) to move downward away from the ferrofluid droplet (710), so that the morphology of the ferrofluid droplet (710) changes from a Rosensweig instability state to a surface stable state; The moving module (300) drives the magnetic block (800) to move in the front-back direction, and the ferrofluid droplet (710) follows the magnetic block (800) to move in the same direction on the test substrate (700) under the magnetic field line distribution of the magnetic block (800). Under the irradiation of the excitation light source (600), the camera (400) captures the fluorescence signal of the residual particles of the ferrofluid droplet (710) during the movement. Image processing and fluorescence intensity distribution analysis are performed on the images captured by the camera (400), and the residual area of the fluorescence signal is calculated to obtain the effect of ferrofluid on drug transportation.